{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-007858","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.245040+00:00","generated_at":"2026-05-30T02:33:36.051615+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aethlon Medical enrolls first patient in Hemopurifier cancer trial for solid tumors","bullets":["First patient enrolled Oct 29, 2024 at Royal Adelaide Hospital; eligibility confirmed Nov 8.","Trial is safety, feasibility, dose-finding for Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.","Two-month run-in on anti-PD-1 therapy; if no tumor improvement, patient treated with Hemopurifier.","Trial targets 9-18 patients; primary endpoint is adverse events and safety lab changes.","Exploratory endpoints measure extracellular vesicle reduction and T cell activity improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-007858","json":"https://secwatch.observer/filing/0001683168-24-007858.json","markdown":"https://secwatch.observer/filing/0001683168-24-007858.md","text":"https://secwatch.observer/filing/0001683168-24-007858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316824007858/0001683168-24-007858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316824007858/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:33:36.051615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}